The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck

Hematological toxicity is the most common complication of chemotherapy. The most dangerous manifestation of hematological toxicity is febrile neutropenia (FN). FN reduces survival, increases the risk of death, the frequency of infectious complications, hospitalizations, the cost of treatment. The ri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Editorial Board
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	malignant neoplasms of the head and neck hematological toxicity myelotoxicity febrile neutropenia granulocyte colony-stimulating factors filgrastim empegfilgrastim prevention Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/56c13e81c4444461a7fdf056a0d54037
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:56c13e81c4444461a7fdf056a0d54037
record_format	dspace
spelling	oai:doaj.org-article:56c13e81c4444461a7fdf056a0d540372021-11-30T16:55:01ZThe importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck1815-14341815-144210.26442/18151434.2021.2.201018https://doaj.org/article/56c13e81c4444461a7fdf056a0d540372021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/77948/58537https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Hematological toxicity is the most common complication of chemotherapy. The most dangerous manifestation of hematological toxicity is febrile neutropenia (FN). FN reduces survival, increases the risk of death, the frequency of infectious complications, hospitalizations, the cost of treatment. The risk of FN should be assessed before the beginning of the therapy, using the general algorithm from the protocol to prevent FN applying the granulocyte colony-stimulating factors (G-CSF). G-CSF for the prevention is required throughout all cycles of myelosuppressive therapy. For the prevention of FN, the most effective is the use of PEGylated G-CSF. Patients with head and neck squamous cell carcinoma, receiving the TPF or DCF regimen, combined with docetaxel and cisplatin, are included in the group of routine primary prophylaxis for neutropenia. In case of developing 34 grade FN in these patients, the use of PEGylated G-CSF (empegfilgrastim) is preferable.Editorial BoardIP Habib O.N.articlemalignant neoplasms of the head and neckhematological toxicitymyelotoxicityfebrile neutropeniagranulocyte colony-stimulating factorsfilgrastimempegfilgrastimpreventionNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 356-360 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	malignant neoplasms of the head and neck hematological toxicity myelotoxicity febrile neutropenia granulocyte colony-stimulating factors filgrastim empegfilgrastim prevention Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	malignant neoplasms of the head and neck hematological toxicity myelotoxicity febrile neutropenia granulocyte colony-stimulating factors filgrastim empegfilgrastim prevention Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Editorial Board The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
description	Hematological toxicity is the most common complication of chemotherapy. The most dangerous manifestation of hematological toxicity is febrile neutropenia (FN). FN reduces survival, increases the risk of death, the frequency of infectious complications, hospitalizations, the cost of treatment. The risk of FN should be assessed before the beginning of the therapy, using the general algorithm from the protocol to prevent FN applying the granulocyte colony-stimulating factors (G-CSF). G-CSF for the prevention is required throughout all cycles of myelosuppressive therapy. For the prevention of FN, the most effective is the use of PEGylated G-CSF. Patients with head and neck squamous cell carcinoma, receiving the TPF or DCF regimen, combined with docetaxel and cisplatin, are included in the group of routine primary prophylaxis for neutropenia. In case of developing 34 grade FN in these patients, the use of PEGylated G-CSF (empegfilgrastim) is preferable.
format	article
author	Editorial Board
author_facet	Editorial Board
author_sort	Editorial Board
title	The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
title_short	The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
title_full	The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
title_fullStr	The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
title_full_unstemmed	The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
title_sort	importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/56c13e81c4444461a7fdf056a0d54037
work_keys_str_mv	AT editorialboard theimportanceofthepreventionoftreatmentinducedneutropeniainpatientswithmalignantneoplasmsoftheheadandneck AT editorialboard importanceofthepreventionoftreatmentinducedneutropeniainpatientswithmalignantneoplasmsoftheheadandneck
_version_	1718406445846757376

The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck

Ejemplares similares